Presented by Dr. Keefe Chng, Chief Scientific Officer and Site Head, Crown Bioscience Louisiana (CBLA, Inc.) and Dr. Judith Gorski, Global Director of Scientific Engagement, Crown Bioscience Inc.
Learn how to design the most optimal Non-GLP Toxicology rodent and NHP studies, to generate robust, high quality data for maximum confidence in selecting new drug candidates and regulatory submissions.
Presented by Dr. Judith Gorski, Global Director, Scientific Engagement, Crown Bioscience Inc.
Discover CrownBio's unique continuum of translational platforms modeling diabetes and metabolic syndrome pathophysiology, progression, and complications, and learn how these platforms are predicting the efficacy and safety of anti-diabetic therapies in humans.
Presented by Dr. Mark Yorek, Professor of Medicine at University of Iowa and Associate Chief of Staff for Research at Iowa City VA.
Learn more on the challenges in modeling diabetic neuropathy and how the use of improved translational rodent models can impact diabetes and obesity preclinical studies.
Presented by Dr. Michelle Mack, Global Director, Scientific Engagement, Crown Bioscience Inc.
Discover the wide range of in vivo immuno-oncology preclinical models available, and what to consider when choosing the correct mouse analogue or human specific model for your single agent and combination studies.
Presented by Dr. John MacDougall, Global Director, Scientific Engagement, Crown Bioscience Inc.
Learn why Mouse Clinical Trials (MCT) using patient-derived xenograft (PDX) models are a key preclinical tool for predicting drug effectiveness, targeting responder populations, and identifying biomarkers before you enter the clinic. Discover the various types of MCT, and identify which method will be best to progress your drug development program.